Things are as usual moving at ludicrous speed in the world of genomics, but sadly I only have time to post a few pointers to some of the most striking developments.
Speaking of Dan Vorhaus: the superb blog Genomics Law Report
has just launched a new series, What ELSI is New
, consisting of brief guest posts from a diverse range of authors on emerging ethical, legal and social issues in genomics. Already there have been two instalments posted, one from Hank Greely
and another from Misha Angrist
– both well worth a read. I have also committed to writing my own contribution (it’s on its way, Dan!).
Doctors in their second and final years of pathology residency training will take the class – attending lectures and researching the science behind the tests. If they choose, they can look at their own test results, submitting a sample to the genetic testing company Navigenics.
Given that 23andMe now dominates the genome scan market (meaning it will be the company most prospective patients will be using), and that the company plans to offer discounted tests to doctors
, Navigenics seems like a strange choice.